We aimed to test the long-term association between use of SGLT2is, specifically empagliflozin, compared with dipeptidyl peptidase 4 inhibitors (DPP4is), and kidney outcomes, with specific emphasis on populations without evidence of cardiovascular and kidney disease. The gene discussed is DPP4; the disease is kidney disorder.